Role of procalcitonin in diagnosis of neonatal sepsis and procalcitonin guided duration of antibiotic therapy
DOI:
https://doi.org/10.18203/2349-3291.ijcp20203088Keywords:
C-reactive protein, Neonatal sepsis, ProcalcitoninAbstract
Background: Neonatal sepsis is one of the important causes of neonatal morbidity and mortality particularly in the developing countries. Accurate and quick diagnosis is difficult because clinical presentation is non-specific, bacterial cultures are time-consuming and other laboratory tests lack sensitivity and specificity. Procalcitonin (PCT) is often reported to be more superior to C-reactive protein (CRP), being more sensitive and specific, starts to rise earlier and returns to normal concentration more rapidly than CRP.
Methods: It is a hospital based prospective observational study. Blood samples were obtained and analyzed for blood culture, septic screen including serum CRP and PCT. Neonates were categorized into proven sepsis (n=39), probable sepsis (n=21) and clinical sepsis (n=40) groups on the basis of laboratory findings and risk factors. Data was analyzed by using standard statistical tests using SPSS 16.
Results: Out of 100 cases, elevated PCT level >0.5 ng/dl was detected in 75 and >2 ng/dl was detected in 51 whereas CRP was positive only in 61 cases. Among the 39 culture positive cases, elevated serum PCT level was noticed in 39 (100%) cases whereas CRP level was noticed in 30 (76.9%) cases. Mean PCT levels were significantly high according to infection severity (P<0.01). Procalcitonin (sensitivity 87.2%, specificity 72.13%, positive predictive value 66.7% and negative predictive value 89.8% and with p value of <0.001) is more superior than CRP to predict sepsis in neonate. The mean duration of antibiotic therapy was 12.46±4.62 days in definite sepsis, 4.53±1.78 days in probable sepsis group and in clinical sepsis group 3.75±1.33 days by serial PCT measurement.
Conclusions: Serum PCT levels >2 ng/dl has got a better sensitivity and NPV, which help us not only in the early diagnosis but also in the prognosis and duration of antibiotic therapy.
References
Stoll BJ, Hansen NI, Sanchez PJ. Early-onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817-26.
Hasan F, Khan SA, Maharoof MK, Muhammed N. Role of procalcitonin in early diagnosis of neonatal sepsis. Int J Contemp Pediatr. 2017;4:383-9.
National Neonatal Perinatal Database Network: report for 2002-2003. Available at: http://www.newbornwhocc.org/pdf/nnpd_report_2002-03.
Investigators of the Delhi Neonatal Infection Study (DeNIS) collaboration. Characterization and antimicrobial resistance of sepsis pathogens in neonates born in tertiary care centers in Delhi India: a cohort study. Lancet Glob Health. 2016;4:e752-60.
Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, et al. Access to effective antimicrobials: a worldwide challenge. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016;387:168-75.
Ruan L, Chen GY, Liu Z, Zhao Y, Xu GY, Li SF, Li et al. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review. Critical Care. 2018 Dec;22(1):1-9.
Puopolo KM, Benitz WE, Zaoutis TE, NEWBORN COFA, DISEASES COI. Management of neonates born at ≤34 6/7 weeks’ gestation with suspected or proven early-onset bacterial sepsis. Pediatrics. 2018;142(6).
Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J. 1997;16:735-747.
Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Meta. 1994;79:1605‑8.
Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, et al. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015;385:430-40.
Al-Zahrani AK, Ghonaim MM, Hussein YM, Eed EM, Khalifa AS, Dorgham LS. Evaluation of recent methods versus conventional methods for diagnosis of early-onset neonatal sepsis. J Infect Dev Ctries. 2015;9(4):388-93.
Gilfillan M, Bhandari V. Neonatal sepsis biomarkers: where are we now?. Research Reports in Neonatol. 2019 Mar 14;9:9-20.
Park IH, Lee SH, Yu ST, Oh YK. Serum procalcitonin as a diagnostic marker of neonatal sepsis. Korean J Pediatr. 2014;57(10):440-5.
Hakeem A, Mohsen A, Kamel BA. Role of procalcitonin in the diagnosis of neonatal sepsis. Int. J Adv Res Biol Sci. 2015;2(3):48-54.
Raghavan M, Mondal GP, Bhat BV, Srinivasan S. Perinatal risk factors in neonatal infections. Indian J Pediatr. 1992;59:335-40.
Lim WH, Lien R, Huang YC, Chiang MC, Fu RH, Chu SM, et al. Prevalence and pathogen distribution of neonatal sepsis among very-low-birth-weight infants. Pediatr Neonatol. 2012 Aug; 53(4):228-34.
Jaswal RS, Kaushal RK, Goel A, Pathania K. Role of C-reactive protein in deciding duration of antibiotic therapy in neonatal septicemia. Indian pediatrics. 2003 Sep 1;40(9):880-3.
Laurent R, Caroline S, Eric K, D'herbomez M, François F. A composite score combining procalcitonin, C-reactive protein, and the temperature has a high positive predictive value for the diagnosis of intensive care-acquired infections. BMC Infectious Diseases. 2013;13:159.
Gerdes JS. Clinicopathologic approach to the diagnosis of neonatal sepsis. Clin Perinatol 1991;18:361-81.
Waliullah SM, Islam MN, Siddika M, Hossain MA, Jahan I, Chowdhury AK. Evaluation of simple hematological screen for early diagnosis of neonatal sepsis. MMJ. 2010 Jan;19(1):41-7.
Sucilathangam G, Amuthavalli K, Velvizhi G, Ashihabegum MA, Jeyamurugan T, Palaniappan N. Early diagnostic markers for neonatal sepsis: comparing procalcitonin (PCT) and C-reactive protein (CRP). J Clin Diag Res. 2012 May;6(4):627-31.
Koksal N, Harmanci R, Çetinkaya M, Hacimustafaoglu M. Role of procalcitonin and CRP in diagnosis and follow-up of neonatal sepsis. Turk J Pediatr. 2007;49(1):21‐9.
Sakha K, Husseini MB, Seyyedsadri N. The role of the procalcitonin in the diagnosis of neonatal sepsis and correlation between procalcitonin and C-reactive protein in these patients. Pak J Biol Sci. 2008;11:1785-90.
Chiesa C, Pellegrini G, Panero A, Osborn JF, Signore F, Assumma M, et al. C-reactive protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness severity, risk status, antenatal and perinatal complications, and infection. Clin Chem. 2003;49(1):60‐8.
Esmat MM, Hasan A, Moghazy HM, Sadek AA. Procalcitonin or C-reactive protein or both for diagnosis of neonatal sepsis. J Appl Sci Res. 2012;8:4615-23.
Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, et al. The Complete Sequence of Human Preprocalcitonin. FEBS Lett. 1984 Feb 13;167(1):93-7.
Resh B, Gusenleitner W, Muller WD. Procalcitonin and interleukin-6 in the diagnosis of early-onset sepsis in neonates. Acta Pediatr. 2003;92:243-5.
Guibordenche J, Bedu A, Petzold L. Biochemical markers of neonatal sepsis: Value of procalcitonin in the emergency setting. Ann Clin Biochem. 2002;39:130-5.
Adib M, Bakhshiani Z, Navaei F, Fosoul F, Fouladi S, Kazemzadeh H. Procalcitonin: A Reliable Marker for the Diagnosis of Neonatal Sepsis. Iran J Basic Med Sci. 2012;15(1):777.
Rajeev D, Honnumurthy JB, Avinash SS. Predictability of biomarkers in the diagnosis of neonatal sepsis: a cross-sectional study. Int J Contemp Pediatr. 2016;3:485-90.
Atlıhan F, Akagündüz B, Genel F, Bak M, Can D. Procalcitonin: a marker of neonatal sepsis. J Trop Pediatr. 2002;48(1):10‐4.
Stocker M, Van Herk W, El Helou S, Dutta S, Fontana MS, Schuerman FA, et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017;390(10097):871-81.
